hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06314646, orgStudyIdInfo id: 3747, briefTitle: Transanal Transection and Single-stapled Anastomosis (TTSS) in Rectal Cancer Patients, acronym: TTSS-REC, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-31, primaryCompletionDateStruct date: 2027-05-31, completionDateStruct date: 2027-12-31, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-20, sponsorCollaboratorsModule leadSponsor name: Istituto Clinico Humanitas, class: OTHER, descriptionModule briefSummary: The Transanal Transection and Single-Stapled anastomosis (TTSS) technique may be a valid alternative to traditional double-stapled anastomosis for low rectal cancer surgery. This study aims to compare the postoperative and functional outcomes of patients receiving TTSS and traditional double-stapled anastomosis., conditionsModule conditions: Rectal Cancer, conditions: Surgery, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 472, type: ESTIMATED, armsInterventionsModule interventions name: Transanal Transection and Single-Stapled anastomosis (TTSS), interventions name: Double-stapled Total Mesorectal Excision (TME), outcomesModule primaryOutcomes measure: Rate of anastomotic leak, secondaryOutcomes measure: Rate of postoperative complications, secondaryOutcomes measure: Postoperative Recovery Profile (PRP) score, secondaryOutcomes measure: Proportion of patients fit for stoma closure, secondaryOutcomes measure: Healthcare costs, secondaryOutcomes measure: Low Anterior Resection Syndrome (LARS) score, secondaryOutcomes measure: Low Anterior Resection Syndrome (LARS) score, secondaryOutcomes measure: Low Anterior Resection Syndrome (LARS) score, secondaryOutcomes measure: Cancer recurrence, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06314633, orgStudyIdInfo id: ICO-2023-13, briefTitle: Socioeconomic Determinants of the Chemical Exposome and Its Genotoxic Effects in Children, acronym: PESTIFOL, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-29, primaryCompletionDateStruct date: 2026-01, completionDateStruct date: 2026-06, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-21, sponsorCollaboratorsModule leadSponsor name: Institut Cancerologie de l'Ouest, class: OTHER, collaborators name: ANSES, descriptionModule briefSummary: PESTIFOL will include children over 8 and under 12 years old of different socioeconomic positions (SEP), mostly living in the region of Pays de la Loire. This approach should enable us to assess the impact of the SEP, and therefore social inequalities, on chemical expositions and DNA damage, and to characterize which (classes/mixture of) pollutants are major source of DNA damage. The study will also address potential effects associated with geographical location on the exposome and its biological consequences., conditionsModule conditions: Healthy Volunteer Children, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Hair collection and parents questionnaires, primaryPurpose: HEALTH_SERVICES_RESEARCH, maskingInfo masking: NONE, enrollmentInfo count: 140, type: ESTIMATED, armsInterventionsModule interventions name: Hair cut, interventions name: Socio-economic questionnaires, outcomesModule primaryOutcomes measure: Describe DNA damage, primaryOutcomes measure: Describe DNA damage, primaryOutcomes measure: Describe socio-economic characteristics., primaryOutcomes measure: Describe socio-economic characteristics., secondaryOutcomes measure: Characterize chemical exposome variations, secondaryOutcomes measure: Characterize chemical exposome variations, secondaryOutcomes measure: Characterize socio-economic indicators, secondaryOutcomes measure: Characterize socio-economic indicators, geographical area, seasons, secondaryOutcomes measure: Characterize socio-economic indicators, geographical area, seasons, secondaryOutcomes measure: Characterize socio-economic indicators, geographical area, seasons, secondaryOutcomes measure: Describe DNA damage, secondaryOutcomes measure: Describe DNA damage, eligibilityModule sex: ALL, minimumAge: 8 Years, maximumAge: 12 Years, stdAges: CHILD, contactsLocationsModule locations facility: Institut de Cancérologie de l'ouest, status: RECRUITING, city: Saint-Herblain, zip: 44800, country: France, contacts name: Marie ROBERT, MD, role: CONTACT, email: Marie.Robert@ico.unicancer.fr, contacts name: Pierre VIDI, PhD, role: CONTACT, email: Pierre.Vidi@ico.unicancer.fr, contacts name: Marie ROBERT, MD, role: PRINCIPAL_INVESTIGATOR, contacts name: PIERRE VIDI, PhD, role: SUB_INVESTIGATOR, contacts name: Martine BELLANGER, PhD, role: SUB_INVESTIGATOR, geoPoint lat: 47.21765, lon: -1.64841, hasResults: False
protocolSection identificationModule nctId: NCT06314594, orgStudyIdInfo id: 2024KY920, briefTitle: the Individualized Stepwise Treatment Mode of Adolescent Idiopathic Scoliosis, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-12-20, primaryCompletionDateStruct date: 2025-12-01, completionDateStruct date: 2026-12-01, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: Hangzhou Medical College, class: OTHER, descriptionModule briefSummary: Based on the risk factors affecting adolescent scoliosis found in the previous social survey, this project adopts the paradigm based on transfer learning and semi-supervised learning, and uses mathematical methods such as multiple learning methods and Transformer image classification algorithms to develop and verify the early warning model and stepped treatment model of adolescent scoliosis, and conducts cost-effect analysis., conditionsModule conditions: Adolescent Scoliosis, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 76, type: ESTIMATED, armsInterventionsModule interventions name: Conventional treatment, interventions name: intervention treatment, outcomesModule primaryOutcomes measure: Number of Cobb angles, primaryOutcomes measure: Accuracy of new screening modalities, primaryOutcomes measure: Hamilton Depression Volume, eligibilityModule sex: ALL, minimumAge: 3 Years, maximumAge: 18 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: the Affiliated Zhejiang Provincial People's Hospital to Hangzhou Medical College., status: RECRUITING, city: Hangzhou, state: Zhejiang, zip: 311000, country: China, contacts name: Xinyun Dr LI, Doctor, role: CONTACT, phone: 8618069783240, email: lxyjasmine2010@163.com, geoPoint lat: 30.29365, lon: 120.16142, hasResults: False
protocolSection identificationModule nctId: NCT06314581, orgStudyIdInfo id: 673_BPPV-Teaching, briefTitle: Effect of a Multifaceted Educational Intervention on the Implementation of Evidence-based Practices for Benign Paroxysmal Positional Vertigo in an Emergency Department, acronym: BPPV-Teaching, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-05-01, primaryCompletionDateStruct date: 2024-05-01, completionDateStruct date: 2024-12-01, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: Fondation Hôpital Saint-Joseph, class: OTHER, descriptionModule briefSummary: Acute vertigo accounts for around 4% of emergency room visits. Triggered episodic vestibular syndrome is the most commonly encountered symptomatic context. BPPV (Benign Paroxysmal Positional Vertigo) is the main cause, representing 40-50% of the vertigo cases assessed in emergency departments. It results from the migration of calcium carbonate particles (otoliths), from the sticky membrane of the utricle and saccule of the inner ear, to one of the 3 semicircular canals (SCC), posterior, horizontal or lateral, and anterior. It occurs idiopathically with head movement, through degeneration, or following head trauma. The otolith impulse causes the endolymph to move, temporarily and aberrantly displacing the cup of the affected canal, resulting in the transmission of erroneous information to the vestibular nuclei. This leads to the sudden onset of vertigo and eye deviation, resulting in transient nystagmus. The location of the displaced otoliths determines the variant of BPPV: BPPV of the posterior semicircular canal is the most common (around 65% of BPPVs), followed by BPPV of the horizontal canal, while BPPV of the anterior canal is rare, as it resolves spontaneously and rapidly. Although a benign condition, BPPV leads 9 times out of 10 to a medical consultation, interruption of daily activities, or sick leave. Untreated, it will usually recur, and can impact on patients' quality of life., conditionsModule conditions: Benign Paroxysmal Positional Vertigo, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 185, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: accurate BPPV diagnostics, secondaryOutcomes measure: therapeutic maneuvers performed, secondaryOutcomes measure: Satisfaction of clinicians who received the educational interventio, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Groupe Hospitalier Paris Saint-Joseph, status: RECRUITING, city: Paris, zip: 75014, country: France, contacts name: Camille GERLIER, MD, role: CONTACT, phone: +331441228023, email: cgerlier@ghpsj.fr, geoPoint lat: 48.85341, lon: 2.3488, hasResults: False
protocolSection identificationModule nctId: NCT06314568, orgStudyIdInfo id: 6350, briefTitle: Radiochemotherapy and Interventional Radiotherapy in Vaginal Cancer, acronym: TRIDENT, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-15, primaryCompletionDateStruct date: 2026-03-31, completionDateStruct date: 2028-12-31, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-04-04, sponsorCollaboratorsModule leadSponsor name: Fondazione Policlinico Universitario Agostino Gemelli IRCCS, class: OTHER, descriptionModule briefSummary: Prospective observational multicenter study, aimed at evaluating the effectiveness on local control and cancer-specific survival of radiochemotherapy followed by interventional radiotherapy in patients affected by vaginal cancer, conditionsModule conditions: Vaginal Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 278, type: ESTIMATED, armsInterventionsModule interventions name: Radiochemotherapy plus interventional radiotherapy, outcomesModule primaryOutcomes measure: Local Control, secondaryOutcomes measure: Cancer specific overall survival, secondaryOutcomes measure: Toxicities, secondaryOutcomes measure: Overall survivall, secondaryOutcomes measure: Disease free survivall, secondaryOutcomes measure: Metastasis free survival, secondaryOutcomes measure: Changes in quality of life over time, eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Fondazione Policlinico Universitario A. Gemelli IRCCS, status: RECRUITING, city: Roma, zip: 00168, country: Italy, contacts name: VALENTINA LANCELLOTTA, role: CONTACT, phone: +390630155701, email: valentina.lancellotta@policlinicogemelli.it, contacts name: VALENTINA LANCELLOTTA, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 41.89193, lon: 12.51133, hasResults: False
protocolSection identificationModule nctId: NCT06314555, orgStudyIdInfo id: CEROG2023, briefTitle: Impact of the sFlt-1/PlGF Ratio on Medical Decision-making and on Maternal and Neonatal Outcomes in Women Suspected of Preeclampsia, statusModule overallStatus: COMPLETED, startDateStruct date: 2019-10-01, primaryCompletionDateStruct date: 2021-01-27, completionDateStruct date: 2021-01-27, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: Centre Hospitalier Universitaire de Saint Etienne, class: OTHER, descriptionModule briefSummary: Previous studies demonstrated that Placental Growth Factor (PIGF) and Vascular Endothelial Growth Factor (VEGF) produced by trophoblast cells decreases during Preeclampsia, whereas soluble fms-like tyrosine kinase-1 (sFlt-1), an antiangiogenic factor, increases. The ratio sFlt-1/PlGF has a higher positive predictive value than the isolated measurement. A ratio under 38 exclude risk of imminent preeclampsia and allows to outpatient follow-up with a negative predictive value of 99.3%. A ratio equal or higher than 38 permits to direct high-risk patients towards hospitalization with a positive predictive value of 36.7% of preeclampsia at 4 weeks. These findings suggest that the ratio can be used to select more appropriately women needing hospitalization for suspected preeclampsia., conditionsModule conditions: Preeclampsia Possible, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: PROSPECTIVE, enrollmentInfo count: 314, type: ACTUAL, armsInterventionsModule interventions name: Blood sample, interventions name: Vascular-renal sample, outcomesModule primaryOutcomes measure: Doctor's medical care decisions on Hospitalization, secondaryOutcomes measure: Intensive monitoring, secondaryOutcomes measure: Corticosteroid administration for lung maturation, secondaryOutcomes measure: Birth induction, eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Chu Saint Etienne, city: St Etienne, zip: 42100, country: France, geoPoint lat: 45.43389, lon: 4.39, hasResults: False
protocolSection identificationModule nctId: NCT06314542, orgStudyIdInfo id: REC-001, briefTitle: Quantitative Evaluation of the Impact of Relaxing Eligibility Criteria for Lung Cancer Based on Real-world Data, statusModule overallStatus: RECRUITING, startDateStruct date: 2013-01-01, primaryCompletionDateStruct date: 2025-12-31, completionDateStruct date: 2026-06-30, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: Cancer Institute and Hospital, Chinese Academy of Medical Sciences, class: OTHER, collaborators name: AstraZeneca, descriptionModule briefSummary: Eligibility criteria for cancer drug trials are generally too stringent, leading to key issues such as low enrolment rates and lack of population diversity. In order to evaluate the REC of NSCLC drug trials, this study will use deep learning methods to construct a structured real-world database of NSCLC across dimensions, and quantitatively assess the independent contribution of changes in each eligibility criterion to patient numbers, clinical efficacy and safety., conditionsModule conditions: Lung Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 50000, type: ESTIMATED, armsInterventionsModule interventions name: relaxing eligibility criteria, outcomesModule primaryOutcomes measure: Scale of eligibility criteria, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Cancer Hospital, Chinese Academy of Medical Sciences, status: RECRUITING, city: Beijing, country: China, contacts name: Ning Li, role: CONTACT, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06314529, orgStudyIdInfo id: 2022-LTF-BHC001, briefTitle: Long-term Follow-up Study of BHC001 for TDT, statusModule overallStatus: RECRUITING, startDateStruct date: 2022-12-14, primaryCompletionDateStruct date: 2036-12-10, completionDateStruct date: 2037-05-10, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: Bioray Laboratories, class: INDUSTRY, collaborators name: The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army, collaborators name: Xiangya Hospital of Central South University, descriptionModule briefSummary: Observe long-term safety risk and long-term efficacy after intravenous infusion of BHC001 in TDT subjects., conditionsModule conditions: Thalassemia, Beta, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: PROSPECTIVE, enrollmentInfo count: 6, type: ESTIMATED, armsInterventionsModule interventions name: Assessments, outcomesModule primaryOutcomes measure: Incidence of hematologic malignancies, primaryOutcomes measure: Frequency, grade, and relationship of SAEs, eligibilityModule sex: ALL, minimumAge: 5 Years, maximumAge: 35 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army, status: RECRUITING, city: Nanning, state: Guangxi, zip: 530021, country: China, contacts name: Xinhua Zhang, PhD, role: CONTACT, geoPoint lat: 22.81667, lon: 108.31667, locations facility: Xiangya Hospital of Central South University, status: RECRUITING, city: Changsha, state: Hunan, zip: 510510, country: China, contacts name: Bin Fu, PhD, role: CONTACT, geoPoint lat: 28.19874, lon: 112.97087, hasResults: False
protocolSection identificationModule nctId: NCT06314516, orgStudyIdInfo id: CRP17122, briefTitle: Influence of Nutrition and Sarcopenia on Esophageal Cancer Outcomes, acronym: INSPECT, statusModule overallStatus: COMPLETED, startDateStruct date: 2017-12-27, primaryCompletionDateStruct date: 2024-02-28, completionDateStruct date: 2024-02-28, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: Benaroya Research Institute, class: OTHER, collaborators name: Imperial College London, descriptionModule briefSummary: Prospective multicenter longitudinal (observational) study recruiting from tertiary centers for the surgical management of esophageal cancer; Virginia Mason Medical Center (Seattle, USA) and St Mary's Hospital (Imperial College, London, UK). This is intended to be a pilot study., conditionsModule conditions: Esophageal Cancer, conditions: Sarcopenia, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 1717, type: ACTUAL, armsInterventionsModule, outcomesModule primaryOutcomes measure: Longitudinal variation in body composition, secondaryOutcomes measure: Patient and disease-specific factors, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 90 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Virginia Mason Medical Center, city: Seattle, state: Washington, zip: 98101, country: United States, geoPoint lat: 47.60621, lon: -122.33207, documentSection largeDocumentModule largeDocs typeAbbrev: Prot, hasProtocol: True, hasSap: False, hasIcf: False, label: Study Protocol, date: 2019-12-10, uploadDate: 2024-03-11T13:52, filename: Prot_000.pdf, size: 1135477, largeDocs typeAbbrev: ICF, hasProtocol: False, hasSap: False, hasIcf: True, label: Informed Consent Form, date: 2019-01-15, uploadDate: 2024-03-11T13:53, filename: ICF_001.pdf, size: 135983, hasResults: False
protocolSection identificationModule nctId: NCT06314490, orgStudyIdInfo id: ASOSCN2A, briefTitle: Personalized Antisense Oligonucleotide Therapy for Rare Pediatric Genetic Disease: SCN2A, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2024-02-16, primaryCompletionDateStruct date: 2026-02-16, completionDateStruct date: 2026-02-16, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: University of California, San Diego, class: OTHER, collaborators name: California Institute for Regenerative Medicine (CIRM), collaborators name: n-Lorem Foundation, descriptionModule briefSummary: This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single pediatric participant with SCN2A associated developmental epileptic encephalopathy, conditionsModule conditions: Genetic Disease, designModule studyType: INTERVENTIONAL, phases: PHASE1, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 1, type: ACTUAL, armsInterventionsModule interventions name: nL-SCN2A-002, outcomesModule primaryOutcomes measure: Seizure frequency, primaryOutcomes measure: Motor function as measured by Dyskinetic Cerebral Palsy Functional Impact Scale, primaryOutcomes measure: Motor function as measured by the motor skills domain of Vineland Adaptive Behavior Scales, primaryOutcomes measure: Motor function as measured by the motor skills domain of Bayley Scales of Infant and Toddler Development, primaryOutcomes measure: Gastrointestinal assessment as measured by the Bristol Stool Chart, secondaryOutcomes measure: Neurodevelopmental Function as measured by Aberrant Behavior Checklist, secondaryOutcomes measure: Neurodevelopmental Function as measured by Observer-Reported Communication Ability Measure, secondaryOutcomes measure: Neurodevelopmental Function as measured by the Vineland Adaptive Behavior Scales, secondaryOutcomes measure: Neurodevelopmental Function as measured by the Bayley Scales of Infant and Toddler Development, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Rady Children's Hospital, city: San Diego, state: California, zip: 92123, country: United States, geoPoint lat: 32.71533, lon: -117.15726, hasResults: False
protocolSection identificationModule nctId: NCT06314477, orgStudyIdInfo id: HCB/2022/1204, briefTitle: Effect of CPAP Treatment in Patients With Severe Uncontrolled Asthma: The ASTHMA-SLEEP Trial, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2026-12, completionDateStruct date: 2026-12, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: Hospital Clinic of Barcelona, class: OTHER, descriptionModule briefSummary: The aim of the study is to evaluate the impact of CPAP treatment on asthma control in patients with severe uncontrolled asthma and obstructive sleep apnea (OSA), conditionsModule conditions: Obstructive Sleep Apnea, conditions: Asthma, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 138, type: ESTIMATED, armsInterventionsModule interventions name: CPAP treatment, interventions name: Hygienic and dietary advice, outcomesModule primaryOutcomes measure: Asthma control questionnaire, primaryOutcomes measure: Asthma control test, secondaryOutcomes measure: Lung function- forced expiratory volume in the first second (FEV1) in spirometry, secondaryOutcomes measure: Lung function-forced vital capacity (FVC) in spriometry, secondaryOutcomes measure: Prevalence of OSA in severe uncontrolled asthma, secondaryOutcomes measure: Inflammatory profile, secondaryOutcomes measure: Quality of life (Abbreviated Asthma Quality of life Questionnaire- mini-AQLQ questionnaire), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False